Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

NCT ID: NCT05959304

Last Updated: 2025-12-24

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-11
• Study Completion Date: 2026-02-28

Brief Summary

The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab. This study is being conducted as part of the post-marketing regulatory commitment to the Indian Health authority.

Detailed Description

This study is a prospective, non-interventional, open-label, single-arm, multi-center phase IV study to evaluate safety and effectiveness of intravitreal injections (IVI) of brolucizumab in patients with diabetic macular edema (DME) for whom a decision has already been made to be treated with brolucizumab, irrespective of the trial participation. The study period for each patient will be 40 weeks from the informed consent and enrolment in the study.

Assessments/investigations shall be performed in accordance to the local clinical practice and the Investigator's assessed response will be collected in the database. Any patient who suffers from intraocular inflammation (IOI) during the study, treatment with brolucizumab will be discontinued.

Data originating from assessments and evaluations performed at routine patient visits will be collected from the patient's medical records at Baseline, i.e., the start of brolucizumab treatment, and approximately at Week 6, Week 12, Week 18, Week 24, Week 32, Week 36, and at Week 40. Safety data (AEs and SAEs) from any time point during the duration of the study.

Conditions

Diabetic Macular Edema

Keywords

Vision Loss; Macular Edema; Metamorphopsia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

brolucizumab 6 mg

brolucizumab 6 mg intravitreal injection

Group Type: EXPERIMENTAL

brolucizumab

Intervention Type: DRUG

There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.

Interventions

brolucizumab

There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and female patients ≥ 18 years old with visual impairment due to DME involving the center of the macula.

2. Patients with type 1 or type 2 diabetes mellitus.

3. Patient or legally acceptable representative (LAR) must provide signed informed consent for participation in the study.

-

Exclusion Criteria

1. Concomitant conditions or ocular disorders in the study eye at screening or Baseline which could, in the opinion of the Investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the study period (e.g., cataract, vitreous hemorrhage, retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause).

2. Patient with existing or suspected ocular or periocular infection in the study eye.

3. Patient with an existing intraocular inflammation (IOI) in the study eye.

4. Patient who has undergone intraocular surgery including laser photocoagulation in the study eye within 3 months prior to enrollment in this study.

5. Patient with uncontrolled glaucoma defined as intraocular pressure > 25 mmHg despite treatment with anti-glaucoma medication, or according to Investigator's judgment.

6. Patient having scar, fibrosis, and atrophy involving the center of the fovea in the study eye.

7. Active proliferative diabetic retinopathy in the study eye as per Investigator.

8. Patient having history of cardiac or cerebral ischemia in last 6 months prior to enrollment in this study.

9. Previous treatment with any anti-VEGF drugs, steroids (dexamethasone intravitreal implant or triamcinolone acetonide) or other investigational drugs in the study eye.

10. Pregnant or nursing (lactating) women at screening, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG pregnancy test.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Novartis Investigative Site

Ahmedabad, Gujarat, India

Novartis Investigative Site

Bangalore, Karnataka, India

Novartis Investigative Site

Kochi, Kerala, India

Novartis Investigative Site

Chennai, Tamil Nadu, India

Novartis Investigative Site

Kolkata, West Bengal, India

Novartis Investigative Site

Coimbatore, , India

Novartis Investigative Site

Kolkata, , India

Novartis Investigative Site

New Delhi, , India

Countries

India

Other Identifiers

CRTH258BIN01

Identifier Type: -

Identifier Source: org_study_id